What does AUBELPHARMA do?

AUBELPHARMA is a pharmacy in Aubel. Public Limited, started on 11 December 1989, 1 establishment.

What is the address of AUBELPHARMA?

The registered office of AUBELPHARMA is located at Place Nicolaï 9, 4880 Aubel.

Is AUBELPHARMA still active?

Yes. According to the CBE (30 October 2026) AUBELPHARMA is active, legal situation “Normale toestand”, started on 11 December 1989.

Is AUBELPHARMA registered on Peppol?

Yes, AUBELPHARMA is registered on the Peppol network with ID 0208:0439272715.

What is the enterprise number of AUBELPHARMA?

The enterprise number of AUBELPHARMA is BE0439272715.

When was AUBELPHARMA founded?

AUBELPHARMA was founded on 11 December 1989.

Who are the directors of AUBELPHARMA?

According to the 2025 annual accounts, the directors of AUBELPHARMA are: MEECKERS FRERES BV, MEECKERS XAVIER MANAGEMENT VOF.

Is AUBELPHARMA a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 11 December 1989; 5 annual accounts filed, latest fiscal year 2025; 2 directors known from the annual account.

How much profit did AUBELPHARMA make in 2025?

AUBELPHARMA posted a profit after taxes of € 103,467 in financial year 2025.

What is the revenue of AUBELPHARMA?

As a small company, AUBELPHARMA is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 216,455.

How much does an employee at AUBELPHARMA earn?

The average wage cost per full-time employee at AUBELPHARMA was € 60,400 in 2025: staff costs of € 60,366 for 1 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does AUBELPHARMA have?

According to the 2025 annual accounts, AUBELPHARMA has 1 full-time equivalents (FTE).

AUBELPHARMA (Public Limited) - Aubel - BE0439272715

Dossier AUBELPHARMA, printed on 30 October 2026 from databakkes.be/en/0439272715/aubelpharma. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

AUBELPHARMA from Aubel, company number BE0439272715, closed financial year 2025 with a result of € 103,467 after tax. For that financial year AUBELPHARMA recorded a gross margin of € 216,455 and equity of € 110,565. Compared with financial year 2024, the result moved from € 103,272 to € 103,467. Profitable, and profit is growing. The buffer is growing. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on August 14, 2026.

What it is worth Growing

€ 110,565

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 103,467

Profit after tax over the fiscal year.

Cash in the bank

€ 289,576

▲ 36% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 103,400 paid out

100 % of the profit went to the shareholders, mostly to MEECKERS FRERES (100 % of the shares). That is where the money ends up.

People and assets in 2025

Full-time equivalents

Average over the fiscal year, from the social balance sheet.

Wage cost

€ 60,366

▲ 11% vs 2024

€ 60,400 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Debts at end 2025

Bank debt ≈ 8 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 200,888

▼ 11% vs 2024

€ 25,162 is repaid this year. At this pace the long-term loan is gone in ≈ 8 years.

Owed to suppliers

€ 30,921

▼ 10% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 9,799

▼ 15% vs 2024

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 180,033 Gross margin 2022: € 180,033 First fiscal year in the series	€ 181,831 Gross margin 2023: € 181,831 ▲ 1% vs 2022 (€ 180,033) Favourable step	€ 218,553 Gross margin 2024: € 218,553 ▲ 20% vs 2023 (€ 181,831) Favourable step	€ 216,455 Gross margin 2025: € 216,455 ▼ 1% vs 2024 (€ 218,553) Unfavourable step	▼ 1%
Profit after taxes	€ 128,949 Profit after taxes 2022: € 128,949 First fiscal year in the series	€ 120,462 Profit after taxes 2023: € 120,462 ▼ 7% vs 2022 (€ 128,949) Unfavourable step	€ 103,272 Profit after taxes 2024: € 103,272 ▼ 14% vs 2023 (€ 120,462) Unfavourable step	€ 103,467 Profit after taxes 2025: € 103,467 Unchanged (€ 103,272) Favourable step
Equity	€ 109,764 Equity 2022: € 109,764 First fiscal year in the series	€ 110,226 Equity 2023: € 110,226 Unchanged (€ 109,764) Favourable step	€ 110,499 Equity 2024: € 110,499 Unchanged (€ 110,226) Favourable step	€ 110,565 Equity 2025: € 110,565 Unchanged (€ 110,499) Favourable step
Total debts	€ 586,075 Total debts 2022: € 586,075 First fiscal year in the series	€ 622,292 Total debts 2023: € 622,292 ▲ 6% vs 2022 (€ 586,075) Unfavourable step	€ 547,877 Total debts 2024: € 547,877 ▼ 12% vs 2023 (€ 622,292) Favourable step	€ 586,278 Total debts 2025: € 586,278 ▲ 7% vs 2024 (€ 547,877) Unfavourable step	▲ 7%
Cash	€ 189,670 Cash 2022: € 189,670 First fiscal year in the series	€ 261,662 Cash 2023: € 261,662 ▲ 38% vs 2022 (€ 189,670) Favourable step	€ 213,155 Cash 2024: € 213,155 ▼ 19% vs 2023 (€ 261,662) Unfavourable step	€ 289,576 Cash 2025: € 289,576 ▲ 36% vs 2024 (€ 213,155) Favourable step	▲ 36%
Land & buildings	€ 225,700 Land & buildings 2022: € 225,700 First fiscal year in the series	€ 203,685 Land & buildings 2023: € 203,685 ▼ 10% vs 2022 (€ 225,700) Unchanged	€ 182,782 Land & buildings 2024: € 182,782 ▼ 10% vs 2023 (€ 203,685) Unchanged	€ 162,056 Land & buildings 2025: € 162,056 ▼ 11% vs 2024 (€ 182,782) Unchanged	▼ 11%
Retained profit	€ 47,764 Retained profit 2022: € 47,764 First fiscal year in the series	€ 48,226 Retained profit 2023: € 48,226 ▲ 1% vs 2022 (€ 47,764) Favourable step	€ 48,499 Retained profit 2024: € 48,499 ▲ 1% vs 2023 (€ 48,226) Favourable step	€ 48,565 Retained profit 2025: € 48,565 Unchanged (€ 48,499) Favourable step
Dividend	€ 111,500 Dividend 2022: € 111,500 First fiscal year in the series	€ 120,000 Dividend 2023: € 120,000 ▲ 8% vs 2022 (€ 111,500) Unchanged	€ 103,000 Dividend 2024: € 103,000 ▼ 14% vs 2023 (€ 120,000) Unchanged	€ 103,400 Dividend 2025: € 103,400 Unchanged (€ 103,000) Unchanged
Bank debt	€ 287,843 Bank debt 2022: € 287,843 First fiscal year in the series	€ 249,049 Bank debt 2023: € 249,049 ▼ 13% vs 2022 (€ 287,843) Favourable step	€ 225,314 Bank debt 2024: € 225,314 ▼ 10% vs 2023 (€ 249,049) Favourable step	€ 200,888 Bank debt 2025: € 200,888 ▼ 11% vs 2024 (€ 225,314) Favourable step	▼ 11%
Balance sheet total	€ 695,839 Balance sheet total 2022: € 695,839 First fiscal year in the series	€ 732,519 Balance sheet total 2023: € 732,519 ▲ 5% vs 2022 (€ 695,839) Unchanged	€ 658,376 Balance sheet total 2024: € 658,376 ▼ 10% vs 2023 (€ 732,519) Unchanged	€ 696,844 Balance sheet total 2025: € 696,844 ▲ 6% vs 2024 (€ 658,376) Unchanged	▲ 6%
Employees (FTE)	-	1 Employees (FTE) 2023: 1 First fiscal year in the series	1 Employees (FTE) 2024: 1 Unchanged (1) Unchanged	1 Employees (FTE) 2025: 1 Unchanged (1) Unchanged

Key figures of AUBELPHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to AUBELPHARMA?

What happened at AUBELPHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Aug 14, 2026 New annual accounts for financial year 2025: profit of € 103,467. filed late Source: NBB ↗
2018 MEECKERS XAVIER MANAGEMENT VOF became a director. NBB
2007 MEECKERS FRERES BV became a director. NBB
Jan 10, 1990 New establishment in Aubel. KBO
Dec 11, 1989 Start of the company according to the CBE. KBO

In short

From € 128,949 profit in 2022 to € 103,467 profit in 2025.

Paid € 33,199 in corporate taxes since 2022.

Best year ever: 2022, with € 128,949 profit.

On average € 216,500 of value added per employee in 2025.

Original PDFs at the National Bank ↗

Management

MEECKERS FRERES 99.9%

The stake of MEECKERS FRERES comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.

AUBELPHARMA

Behind AUBELPHARMA are MEECKERS FRERES BV and MEECKERS XAVIER MANAGEMENT VOF. The shares are held by MEECKERS FRERES (99.9%).

Directors

According to the 2025 annual accounts

MEECKERS FRERES BV

Managing director · represented by XAVIER MEECKERS

since 2007

MEECKERS XAVIER MANAGEMENT VOF

Director · represented by XAVIER MEECKERS

Also active at: MEECKERS FRERES

since 2018

Shareholders

MEECKERS FRERES

99.9%

Participations

No participations in other companies reported.

Establishments

Establishment units

Physical locations of this company

Registered office

Place Nicolaï 9

4880 Aubel

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.

All companies at this address →

MEECKERS FRERES same network

€ 136,639 gross margin · 2025

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0439.272.715

VAT number

BE 0439.272.715

Registered office

Place Nicolaï 9, 4880 Aubel

Names & denominations

AUBELPHARMA

Enterprise type

Rechtspersoon

Legal form

Public limited company

Legal situation

Normale toestand

Start date

11 December 1989

Peppol

Active · Active since 18 Dec 2025

Activities · NACE

Detailhandel in farmaceutische producten

Apothekers

View on CBE Public ↗ Annual accounts (NBB) ↗

AUBELPHARMA

Financials

What happened to AUBELPHARMA?

Management

Directors

Shareholders

Participations

Establishments

Establishment units

Who else lives here?

Details

Frequently asked questions